Phase I and pharmacokinetic study of erlotinib administered in combination with amrubicin in patients with previously treated, advanced non-small cell lung cancer

• Published in: American journal of clinical oncology Vol. 38; no. 4; p. 405
• Main Authors: Otani, Sakiko, Hamada, Akinobu, Sasaki, Jiichiro, Wada, Mayuko, Yamamoto, Michiko, Ryuge, Shinichiro, Takakura, Akira, Fukui, Tomoya, Yokoba, Masanori, Mitsufuji, Hisashi, Toyooka, Issei, Maki, Sachiyo, Kimura, Michiko, Hayashi, Nobuatsu, Ishihara, Mikiko, Kasajima, Masashi, Hiyoshi, Yasuhiro, Katono, Ken, Asakuma, Maiko, Igawa, Satoshi, Kubota, Masaru, Katagiri, Masato, Saito, Hideyuki, Masuda, Noriyuki
• Format: Journal Article
• Language: English
• Published: United States 01.08.2015
• Subjects: Adenocarcinoma - drug therapy; Adenocarcinoma - pathology; Adult; Aged; Anthracyclines - administration & dosage; Anthracyclines - adverse effects; Anthracyclines - pharmacokinetics; Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - pathology; Disease-Free Survival; Erlotinib Hydrochloride; Erysipelas - chemically induced; Female; Humans; Leukopenia - chemically induced; Lung Neoplasms - drug therapy; Lung Neoplasms - pathology; Male; Middle Aged; Neoplasm Staging; Quinazolines - administration & dosage; Quinazolines - adverse effects; Quinazolines - pharmacokinetics; Treatment Outcome
• ISSN: 1537-453X
• DOI: 10.1097/COC.0b013e3182a2d98d

We conducted a phase I trial of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, combined with amrubicin, a topoisomerase II inhibitor. The aim was to determine the maximum tolerated dose, the dose-limiting toxicities (DLTs), and the pharmacokinetics of this combination in patients with non-small cell lung cancer who had received previous chemotherapy. A total of 9 patients with stage IV disease were treated at 3-week intervals with erlotinib once daily on days 1 through 21 plus a 5-minute intravenous injection of amrubicin on days 1 through 3. The dose levels evaluated were erlotinib (mg/body)/amrubicin (mg/m): 100/30 (n=3), 100/35 (n=3), and 150/30 (n=3). The maximum tolerated dose of erlotinib and amrubicin was 100 mg/body and 35 mg/m because 2 of the 3 patients experienced DLTs during the first cycle of treatment at the third dose level of 150 mg/body and 30 mg/m. Cessation of erlotinib administration for 8 days because of grade 3 leukopenia and grade 3 skin infection (erysipelas) were the DLTs. No drug-drug interactions between erlotinib and amrubicin were observed in this study. The overall response rate was 33%, including 3 partial responses, in the 9 patients. The median progression-free survival for all patients was quite long, 11.3 months, and the median overall survival has not yet been reached. Combined erlotinib plus amrubicin therapy seems to be highly effective, with acceptable toxicity, against non-small cell lung cancer. The recommended dose for phase II studies was erlotinib 100 mg once daily on days 1 through 21, and amrubicin 35 mg/m on days 1 through 3 administered every 21 days.